Call for Abstract
Scientific Program
2nd Annual summit on Cell Signaling and Cancer Therapy, will be organized around the theme “The Scientific Innovations in the field of Cancer Therapy and Cell Signaling”
Cell Signaling 2018 is comprised of 15 tracks and 90 sessions designed to offer comprehensive sessions that address current issues in Cell Signaling 2018.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Cell signaling is highly complex system and extremely specific process that governs many important functions in bacterial and human cells. Each signaling process involves multiple steps, and the major research challenge is to perform suitable experiments and modeling not only to study the individual steps, but also to understand how these steps are perfectly coordinated and regulated to produce the end point response.
Biological networks are complex and dynamic systems that enable living cells to sense and respond to changes in their immediate environment. Although the main components of biological networks have been studied in detail, it remains unclear how cells decode, integrate cell signals and make cell decisions. The Cell Signaling Dynamics group combines both mathematical modeling and experimental approaches to unravel the mechanisms of molecular networks by which extrinsic and intrinsic signals control cell proliferation and differentiation at a systems level.
- Track 1-1Cell to cell signaling
- Track 1-2Systems Biology of TGF-β Signaling Dynamics
- Track 1-3Systems analysis of the adaptation in TGF-β signaling
- Track 1-4Innate and adaptive immune response
- Track 1-5Host interactions related to cell signaling
- Track 1-6Bacterial virulence and drug resistance
- Track 1-7Molecular mechanism of kinase activity
- Track 1-8Organelle crosstalk in membrane dynamics and cell signaling
Cell signaling governs basic cellular activities and coordinates cell actions through a complex coordination of responses to cellular microenvironment. The disruption or errors found within this communication chain gives rise to various diseases and cancers. By understanding cell signaling, diseases may be treated more effectively and cures created.
The complex interaction of the activated receptor with other proteins inside the cell before the ultimate physiological effect of the ligand on the cell's behavior is produced is called signal transduction or cell signaling. Numerous cell signaling pathways exist, including Akt, NF-kB, and Notch signaling. Rockland produces antibodies that assist in research for a variety of these pathways.
- Track 2-1Paracrine, endocrine and autocrine signaling
- Track 2-2Direct signaling across gap junctions
- Track 2-3Signaling pathways and cell surface receptors
- Track 2-4Secondary messenger systems
- Track 2-5Cell signaling pathway modeling
A large number of therapeutic drugs are directed against proteins or are proteins themselves, and protein-related technologies promise to revolutionize our understanding of the complex wiring of biological systems. Protein signaling is the eukaryotic cell’s most important regulatory mechanism to appropriately respond to internal and external cues. This intracellular signaling response is mediated by numerous site-specific post-translational modifications (PTMs) of proteins, including phosphorylation, ubiquitylation, and acetylation. Such regulatory PTMs are involved in virtually all signaling pathways that orchestrate fundamental cellular processes including cell cycle progression, apoptosis, the DNA damage response, autophagy, and metabolism. This meeting will bring together world leading researchers in the area of protein signaling.
- Track 3-1Post-translational modifications in cell signaling
- Track 3-2Passive and regenerative conductions
- Track 3-3Propagation and termination of neurotransmission
- Track 3-4Injury inflammation and pain
Ample number of diseases are caused by defects in signaling pathways. The nature of these defects and how they are induced varies enormously. Pathogenic organisms and viruses, many of which can interfere with signalling events, can cause some of these defects. There are many diseases that can be traced to deformity in the function of cell signalling pathways. The concept of signalsome remodelling and disease provides a framework for considering how deformity in signalling pathways can result in disease. It is convenient to separate these defects into phenotypic remodelling of the signalsome and genotypic remodelling of the signalsome. Most of the serious diseases in humans, such as hypertension, heart disease, diabetes and many forms of mental illness, seem to arise from subtle phenotypic modifications of signalling pathways. Such phenotypic remodelling amend the behaviour of cells so that their normal functions are subverted, leading to disease. Since it has proved difficult to clearly establish this relationship between signalsome remodelling and disease, there has been relatively little progress in designing effective treatments.
- Track 4-1Pathogenic organism and viruses related disease in cell signaling
- Track 4-2Phenotypic and genotypic remodelling of the signalsome
- Track 4-3Cell proliferation and cell differentiation related disease
- Track 4-4Cell proliferation and cell differentiation related disease
Adhesion of cells is a best factor of the architecture of many tissues. Cell adhesion is the process cells interact and attach to a surface, substrate or another cell, mediated by interactions between molecules of the cell surface. Cell adhesion happens from the action of transmembrane glycoproteins, and these comprise selectins, integrins, syndecans, and cadherins. Cellular adhesion is essential in maintaining multicellular structure. Cell adhesion includes like Genomic and Functional Screening. Cell adhesion is also essential for the pathogenesis of infectious organisms. Viruses also have adhesion molecules enforced for viral binding to host cells like in influenza virus.
Cell communication is the depth of biophysics and biochemistry to identify different types of communication methods between living cells. Some of the methods include cell signaling among remains. Both multicellular and unicellular organisms densely build on cell-cell communication. Intercellular introduces to the communication between cells. Membrane vesicle trafficking has a crucial role in intercellular communications in humans and animals, like in synaptic transmission, hormone secretion via vesicular exocytosis.
- Track 5-1Stages of cellular communication
- Track 5-2Molecular profiling including genomics, proteomics, and post translational modifications
- Track 5-3Molecular perturbation including genetic and functional perturbations
- Track 5-4Signal transduction by adhesion receptors
- Track 5-5G-Protein-Coupled Receptors, pancreatic islets, and diabetes
The aim of research in signal transduction is to identify the functions of various signaling pathways in physiological and pathological states. Traditional techniques using biochemical, genetic or cell biological approaches have made crucial grants to our understanding of cellular signaling. Despite, the single-gene approach does not take into account the full complexity of cell signaling. With the connections of omics techniques, huge progress has been made in understanding signaling networks.
The use of schemes for global and quantitative analysis of cells is providing new systems-level insights into signal transduction processes. Recent studies reveal important information about the rates of signal transmission and propagation, help to settle down some general regulatory characteristics of multi-tiered signaling cascades, and illuminate the combinatorial nature of signaling specificity in cell differentiation. Cellular kinase signal transduction pathways are muddled in the regulation of many important cellular processes such as cell survival, differentiation and apoptosis.
- Track 6-1Protein profiling and phosphorylation profiling
- Track 6-2Molecular profiling including genomics, proteomics, and post translational modifications
- Track 6-3Key signaling networks in cancer
- Track 6-4Cell signaling pathways and HIV therapeutics
There are many treatments for cancer. The mission of any treatment is to expel cancerous cells to try to ensure cancer doesn’t return. It can be challenging because even if just one cancerous cells remains after treatment. A lot of experimental cancer treatments are also under development. Sometimes this can be proficient by surgery, radiotherapy, chemotherapy but the susceptibility of cancers to infect adjacent tissue or to spread to distant sites by microscopic metastasis usually limits its effectiveness. Biopsy is another option for cancer treatment.
Angiogenesis inhibitors were once thought to have potential as a silver bullet treatment applicable to many types of cancer, surgical procedures for cancer include mastectomy for breast cancer, prostatectomy for prostate cancer, and lung cancer surgery for non-small cell lung cancer. New approaches to surgery or radiation therapy, new combinations of treatments, or new methods are gene therapy. Palliative therapies should be used to control the pain. Many clinical trials have been conducted for cancer therapy.
- Track 7-1Advances in breast and prostate cancer therapy
- Track 7-2Advances in bone cancer therapy
- Track 7-3Cure with suppressing the cancer to a subclinical state
- Track 7-4Palliative care without curative bound
- Track 7-5Experimental cancer treatment like drug therapies
- Track 7-6Tackling the toughest research challenges
A lot of treatment preferences are available for patients suffering from cancer. Depending on the type of cancer, the stage of the cancer when the patient is diagnosed, and the patient’s overall health, some treatment options may make more sense, or may be more effective, than others.
Chemotherapy indicates to a type of cancer treatment in which a patient is given drugs that are designed to kill cancer cells. One or more drugs, called cytotoxic anti-neoplastic drugs, may be given at a time, either intravenously or orally. Chemotherapy works by targeting cells within the body that divide swiftly, which is one of the main characteristics of cancer cells. Some normal cells also divide rapidly, such as cells in hair follicles and the digestive tract. These cells are also flawed by chemotherapy, which accounts for copious of the side effects patients experience when undergoing treatment.
Radiation treatment refers to a type of cancer treatment in which high-doses of radiation are delivered to cancerous tumors in the body. The beams of radiation pass through the skin and other materials to target a definite location where a tumor is located. Radiation damages the DNA of the cancer cells, causing them to die. The mechanism of receiving radiation treatment is painless, and side effects are often limited to the areas of the body around the tumors that receive the treatment. Other common side effects include fatigue and skin irritation.
- Track 8-1Innovative methods in radiation oncology
- Track 8-2Radiation also used in leukemia, lymphoma, prostate and thyroid cancers
- Track 8-3Side effects of radition therapy like acute, late and cumulative
- Track 8-4Effects of radiation therapy on pituitary system
- Track 8-5External beam and radioisotope therapy and their techniques
- Track 8-6Testing ofgenetic mutations and breast cancer
- Track 8-7Different ways of chemotherapy
- Track 8-8Adverse effects on organs
- Track 8-9Anticancer drugs
- Track 8-10Combination therapy and total remission
Immunotherapy also called biologic therapy, is a type of cancer treatment that expansions the body's natural defenses to fight the cancer. It uses substances made by the body or in a laboratory to improve or restore immune system function.
Targeted therapy is a cancer treatment that uses drugs. It is different from traditional chemotherapy. The drugs known as targeted therapy help stop cancer from developing and expanding. They work by targeting specific genes or proteins. These genes and proteins are found in cancer cells or in cells related to cancer growth, like blood vessel cells.
- Track 9-1Different types of immunotherapy
- Track 9-2Lung and thyroid problems
- Track 9-3Immune system stimulants
- Track 9-4Tumor antigens and anti-tumor response
- Track 9-5Nex-Gen technologies for immunotherapy
- Track 9-6Targeting immune checkpoints
- Track 9-7Small molecules drug and monoclonal antibodies
- Track 9-8Block or turn off signals that tell cancer cells to grow and divide
- Track 9-9Keep cells from living longer than normal
- Track 9-10Cancer immunotherapy and vaccines
- Track 9-11Personalized treatment approach
The cancer stem cell theory, cancers can be originated by cancer stem cells. This makes cancer stem cells prime targets for therapeutic intervention. Eradicating cancer stem cells by efficient targeting agents may have the potential to cure cancer. We summarize recent breakthroughs that have amended our understanding of cancer stem cells, and we discuss the therapeutic strategy of targeting cancer stem cells, a promising future direction for cancer stem cell research.
- Track 10-1Types of stem cell transplants for cancer treatment
- Track 10-2Therapies targeting cancer stem cells
- Track 10-3Autologous, allogeneic and syngeneic stem cell transplant
- Track 10-4Bone marrow transplant
- Track 10-5Mechanistic and mathematical modeling
The analysis of cancer has endured evolutionary changes as understanding of the underlying biological processes has risen. Tumor removal surgeries have been documented in ancient Egypt, hormone therapy and radiation therapy were advanced in the late 19th Century. Chemotherapy, immunotherapy and newer targeted therapies are products of the 20th century. External radiation and radiation implants under the radiation therapy. Common therapies include the biologic therapies, targeted therapies, complementary and alternative therapy also.
From last few years the availability of a wide variety of different therapeutic agents and the identification of sufficient combinations of existing ones that have transformed the way we approach and treat pancreatic cancer. It will feature an investigation of emerging targets for cancer, including intracellular targets, cancer stem cell and checkpoint inhibition. New ways of engaging the immune system will be break out, along with new approaches on how to engineer the next generation of CAR-T cells to be more effective. The field is exploding with opportunities to evolve the next generation therapies against cancer that promise greater capability and less toxicity.
- Track 11-1Novel Products for Cancer and Emerging Targets
- Track 11-2Surgery and therapies
- Track 11-3Blood product donation,transfusion and laser treatment
- Track 11-4Novel method FOLFIRINOX regimen and gemcitabine plus nab-paclitaxel
- Track 11-5Advances in molecular modeling of mucosal injury
The transformation of normal cells into cancer cells and preservance of the malignant state and phenotypes are associated with genetic and epigenetic deregulations, altered cellular signaling responses and aberrant interactions with the microenvironment. These alterations are constantly evolving as tumor cells face changing selective pressures induced by the cells themselves, the microenvironment and drug treatments. Tumors are also complex ecosystems where distant, sometime heterogeneous, subclonal tumor populations and a variety of nontumor cells coexist in a constantly evolving manner. The interactions between molecules and between cells that arise as a result of these alterations and ecosystems are even more complex. The cancer research community is progessively embracing this complexity and adopting a combination of systems biology methods and integrated analyses to understand and predictively model the activity of cancer cells. Systems biology approaches are helping to understand the mechanisms of tumor progression and design more effective cancer therapies.
- Track 12-1Computational modeling and bioinformatics
- Track 12-2Approach in trancriptomics, Metabolomics and high throughput techniques
- Track 12-3Emerging field of Functional genomics and molecular biology
- Track 12-4Cancer system biology
- Track 12-53D structure, epigenetics
- Track 12-6Data integration, modelling and prediction
Cancer pharmacology plays a important role in drug development. In both the laboratory and the clinic, cancer pharmacology has had to adapt to the changing face of drug development by establishing experimental models and target orientated approaches.
Cancer Pharmacology directs on developing experimental approaches to the clinical treatment of cancer through research that bridges the fields of molecular carcinogenesis, biochemical pharmacology, radiation biology, and clinical pharmacology.
Cancer pharmacology is the study of the molecular and cellular mechanisms of cancer cells and the identification of novel therapeutic targets and treatment strategies. An emphasis on difficult to treat breast cancer subtypes, which includes research on cancer stem cells, is leading to discoveries of new disease mechanisms and drug targets.
- Track 13-1Tumor Targeting Strategies
- Track 13-2Hormonal & Biological Agents
- Track 13-3Cancer Drug Targets
- Track 13-4Clinical Trials
- Track 13-5Anticancer Therapeutics
- Track 13-6Research and Analytical Methods
Membrane proteins are proteins that interact with, or are part of, biological membranes. They include integral membrane proteins that are permanently anchored or part of the membrane and peripheral membrane proteins that are only temporarily attached to the lipid bilayer or to other integral proteins. The integral membrane proteins are classified as transmembrane proteins that span across the membrane and integral monotopic proteins that are attached to only one side of the membrane. Membrane proteins are a common type of proteins along with soluble globular proteins, fibrous proteins, and disordered proteins. They are targets of over 50% of all modern medicinal drugs. It is estimated that 20–30% of all genes in most genomes encode membrane proteins.
- Track 14-1Integral membrane proteins
- Track 14-2Peripheral membrane proteins
- Track 14-3Polypeptide toxins
Childhood cancer also known as pediatric cancer is cancer in a child. In the United States, an arbitrarily adopted standard of the ages used are 0–14 years inclusive, that is, up to 14 years 11.9 months of age. However, the definition of childhood cancer sometimes includes adolescents between 15–19 years old. Pediatric oncology is the branch of medicine concerned with the diagnosis and treatment of cancer in children. Cancers including leukemias, lymphomas, brain tumors, bone tumors, and solid tumors.
- Track 15-1Diseases of blood cells including disorders of white cells, red cells, and platelets
- Track 15-2Bleeding disorders
- Track 15-3Brain and other tumors
- Track 15-4Chronic myelogeneous leukemia
- Track 15-5Hepatoblastoma
- Track 15-6Acute lymphoblastic and myeloid leukemia
- Track 15-7Acute myelomonocytic leukemia
- Track 15-8Histiocytosis